Search

Your search keyword '"Brahmi M"' showing total 268 results

Search Constraints

Start Over You searched for: Author "Brahmi M" Remove constraint Author: "Brahmi M"
268 results on '"Brahmi M"'

Search Results

1. Improved nationwide survival of sarcoma patients with a network of reference centers

2. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

3. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

4. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry

5. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years

10. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

11. VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

13. 52O Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study

16. 55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

17. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

19. Surgery in reference centers improves survival of sarcoma patients: a nationwide study

20. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

27. EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial

30. 1525TiP TORNADO: A randomized multicenter open-label phase II study evaluating retifanlimab in combination with neoadjuvant chemotherapy in patients with selected retroperitoneal sarcomas

31. 1506P Role of 18F-FDG PET/CT in the initial staging of very high risk Ewing sarcoma in a prospective multicentric phase II study: Is there still a place for bone marrow sampling?

32. LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib

34. 1761P Clinical description and development of a prognosis score for neurofibromatosis type 1 (NF1) associated GISTs in the RECKGIST cohort: A retrospective study from the French NETSARC+ network

35. 1760P Impact of adjuvant imatinib on recurrence for neurofibromatosis type 1 (NF1) associated GISTs: An analysis of the RECKGIST cohort from the French NETSARC+ network

38. 1718O EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)

40. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

41. 83P Association of lung immune prognostic index (LIPI) with progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials

42. 822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy

Catalog

Books, media, physical & digital resources